ÂÜÀòÂÒÂ×

Larry Altstiel, M.D., Ph.D., joined Pinteon in 2018 as chief medical officer, bringing decades of medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry. Prior to Pinteon, he was CEO of Provectra Therapeutics, Inc. from 2013-2015, developing gene therapies for neurodegenerative diseases. Previously, he served as vice president and head of clinical research at Pfizer. At Pfizer, Larry led the selection, development and oversight of multiple preclinical studies and clinical studies from Phase 1 through Phase 3. He also held senior research and management roles at PGRD, Schwarz Biosciences, Inc., Eisai Medical Research Inc., Schering-Plough and Eli Lilly and Company. At Eli Lilly, he was a senior clinical research physician and group leader for neurodegenerative diseases and discovery research for Alzheimer’s disease, Parkinson’s disease and stroke. Prior to that, he was a neurologist at Mount Sinai Alzheimer’s Disease Research Center and director of behavioral neurology at the Bronx Veterans’ Administration Medical Center. Larry received his Ph.D. in cell biology, virology and physical chemistry from The Rockefeller University, completed a postdoctoral fellowship in cell biology at Harvard University and received an M.D. from the University of Miami Leonard M. Miller School of Medicine. He also completed a residency in neurology at the Neurological Institute of New York, Columbia University College of Physicians and Surgeons.